Immune cell attack: experimental therapy targets sarcoma in teens and young adults

NCT ID NCT04052334

First seen Feb 25, 2026 · Last updated May 01, 2026 · Updated 9 times

Summary

This early-phase trial tested a treatment that uses a patient's own immune cells (called TILs) to fight soft tissue sarcoma. Nine young adults received chemotherapy to lower their immune system, then an infusion of their own tumor-fighting cells plus high-dose IL-2. The main goal was to see if the treatment was safe and if the immune cells could survive in the body.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

Conditions

Explore the condition pages connected to this study.